Abstract:3106 Background: NTRK gene fusion resulting from NTRK1/2/3 genetic alterations occurs in various adult and pediatric cancers, which is one of the most defined driving factors of carcinogenesis. Patients with NTRK fusion positive cancers treated by earlier generation TRK inhibitors achieve rapid and durable responses but can develop on-target resistance. ICP-723 is a highly selective next-generation TRK inhibitor. In preclinical studies, ICP-723 not only markedly inhibits the activity of the wild type TRKA/B/C, but also shows robust activity against resistant mutations, e.g., G595R, F589L or G667C/A/S. A first-in-human clinical study is currently ongoing to evaluate the safety, tolerability, pharmacokinetics (PK) characteristics and efficacy of ICP-723. Methods: This is a multi-center, open-label phase I/II clinical trial, which includes a phase I dose escalation part and a phase II dose expansion part. In the phase I dose escalation, patients with advanced solid tumor, who failed from clinical standard of care or for whom there is currently no effective therapy, will be enrolled. The modified "3+3" method is followed for dose escalation. Results: As of 11Feb2022, a total of 17 patients in phase I dose escalation were treated with ICP-723 at doses of 1 mg QD to 8 mg QD. The median age of the enrolled patients was 54 yrs, (range: 31 to 69 yrs) and ECOG performance status was between 0-1 (58.8% had ECOG PS of 1). Six of 17 patients were confirmed as NTRK gene fusion positive tumors by either prior gene test reports or the central lab gene test. There is no DLT observed in the 6 dose groups. Most AEs were manageable and grade 1-2. The most common TRAEs (> 20%) were asthenia (23.5%), increased ALT (29.7%), increased AST (29.7%) and anemia (29.7%). Gr ≥3 TRAEs were increased ALT (5.9%), increased AST (5.9%), increased CPK (11.8%), neutrophil count decreased (5.9%) and pain (5.9%). The plasma exposure to ICP-723 increased in a dose proportional manner across the observed dosage levels. According to RECIST 1.1 criteria, among the 6 patients with NTRK fusion, the overall response rate (ORR) was 66.7% (4 patients with partial response (PR)), the disease control rate (DCR) was 100%. It is worth noting that one patient with measurable brain metastasis achieved PR with the target brain lesion shrunk from 10 mm to 3 mm. All patients who achieved PR responded to ICP-723 at the first tumor assessment after 4-week treatment and maintained sustained responses to the date of data cutoff. Conclusions: ICP-723 is safe and well-tolerated in patients with advanced solid tumors. Encouraging clinical efficacy including intracranial activity was demonstrated in patients with NTRK gene fusion in various tumor types. Enrollment in phase I is ongoing until the final RP2D is determined, then phase II expansion will be conducted in patients with defined gene alterations. Clinical trial information: NCT04685226.

Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation

Establishing Optimized Staining Protocol and Cutoff Values of Pan-Trk Immunohistochemistry for Detecting NTRK Fusions in Solid Tumors: A Chinese Multicenter Cross-Sectional Study.

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma

The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.

Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer

NTRK fusions in solid tumours: what every pathologist needs to know

[Practical application of immunohistochemistry in pancreatic neuroendocrine neoplasms : Tips and pitfalls]

Safety, Pharmacokinetics (PK), and Clinical Efficacy of ICP-723, a Highly Selective Next-Generation Pan-Trk Inhibitor, in Patients with Solid Tumor.

Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib

Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort

Feasibility of two-step approach for screening NTRK fusion in two major subtypes of non-small cell lung cancer within a large cohort

Expression and Prognostic Impact of NTF3 and TrkC in Hepatocellular Carcinoma.

GISTs with NTRK Gene Fusions: A Clinicopathological, Immunophenotypic, and Molecular Study.

NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications

Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene

MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence in Situ Hybridization Positive Colorectal Carcinomas.

NTRK Therapy among Different Types of Cancers, Review and Future Perspectives

Mutation of neurotrophic tyrosine receptor kinase can promote pan-cancer immunity and the efficacy of immunotherapy

NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC

Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions